NHS publication on potential application of TexRAD
NIHR HSRIC is an academic unit which independently investigates and provides advanced notice of new and emerging medical devices and diagnostics that have the potential to positively impact upon the NHS within the next two years. Before writing the Alert, NIHR HSRIC looked at TexRAD CT texture analysis technology and its potential use for assessing patients with different cancers but particularly for those with lung cancer. The Alert will be distributed within the NHS and to national healthcare organisations and policy makers such as the National Institute for Health and Care Excellence (NICE) and the UK National Screening Committee.
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:
"The Alert from the NHS's research arm is a significant step towards potentially obtaining NICE approval for TexRAD to be used as a clinical tool for assessing patients with lung cancer. This adds to the recently announced clinical adoption study focused on lung cancer being undertaken by Professor Ken Miles at the Princess Alexandra Hospital, Brisbane, Australia. "